Qiuheng Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qiuheng Zhang has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Elaine F. Reed
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA
16 shared publications Elaine F. Reed
UCLA Immunogenetics Center, Department of Pathology & Laboratory Medicine, David Geffen School of Medicine at Los Angeles, CA, USA
8 shared publicationsCarrie Butler
UCLA Immunogenetics Center, Department of Pathology & Laboratory Medicine, David Geffen School of Medicine at Los Angeles, CA, USA
6 shared publicationsDavid Gjertson
Department of Pathology and Laboratory Medicine, University of California, Los Angeles Immunogenetics Center, Los Angeles, CA
6 shared publicationsMichelle Hickey
Department of Pathology and Laboratory Medicine, University of California, Los Angeles Immunogenetics Center, Los Angeles, CA
5 shared publicationsYing Zheng
Department of Pathology and Laboratory Medicine, University of California, Los Angeles Immunogenetics Center, Los Angeles, CA
5 shared publications
Latest Publications
- 12 February 2026
- Published by Elsevier in Human Immunology
- Vol. 87 (4) , 111679
Prevalence and Dynamics of HLA donor-specific antibodies in simultaneous liver-kidney transplantation
- 12 February 2026
- Published by Elsevier in Human Immunology
- Vol. 87 (4) , 111679
Prevalence and Dynamics of HLA donor-specific antibodies in simultaneous liver-kidney transplantation
- 6 May 2025
- Published by Elsevier in Human Immunology
- Vol. 86 (4) , 111323
Preventing hyperacute rejection in a deceased donor kidney transplant recipient
- 6 May 2025
- Published by Elsevier in Human Immunology
- Vol. 86 (4) , 111323
Preventing hyperacute rejection in a deceased donor kidney transplant recipient
- Open Access
- 1 February 2024
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 15, 1352764
Advancing precision in histocompatibility and immunogenetics: a comprehensive review of the UCLA exchange program
Precise typing of human leukocyte antigens (HLA) is crucial for clinical hematopoietic stem cell and solid organ transplantations, transfusion medicine, HLA-related disease association, and drug hypersensitivity analysis. The UCLA Cell Exchange program has played a vital role in providing educational and proficiency testing surveys to HLA laboratories worldwide for the past 5 decades. This article highlights the significant contribution of the UCLA Cell and DNA Exchange Programs in advancing HLA antibody testing, genotyping, crossmatches, and, more recently, virtual crossmatches. Additionally, we discuss future directions of the UCLA Cell Exchange program to support histocompatibility testing to adapt to the fast-evolving field of immunotherapy, tolerance and xenotransplantation.
- 1 February 2024
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 15, 1352764
Open AccessAdvancing precision in histocompatibility and immunogenetics: a comprehensive review of the UCLA exchange program
Precise typing of human leukocyte antigens (HLA) is crucial for clinical hematopoietic stem cell and solid organ transplantations, transfusion medicine, HLA-related disease association, and drug hypersensitivity analysis. The UCLA Cell Exchange program has played a vital role in providing educational and proficiency testing surveys to HLA laboratories worldwide for the past 5 decades. This article highlights the significant contribution of the UCLA Cell and DNA Exchange Programs in advancing HLA antibody testing, genotyping, crossmatches, and, more recently, virtual crossmatches. Additionally, we discuss future directions of the UCLA Cell Exchange program to support histocompatibility testing to adapt to the fast-evolving field of immunotherapy, tolerance and xenotransplantation.
- 25 September 2023
- Published by Wolters Kluwer Health in Transplantation
- Vol. 107 (10) , e274
Virtual Crossmatch: By Any Other Name
- 25 September 2023
- Published by Wolters Kluwer Health in Transplantation
- Vol. 107 (10) , e274
Virtual Crossmatch: By Any Other Name
- Open Access
- 20 July 2023
- Published by Wolters Kluwer Health in Transplantation
- Vol. 107 (8) , 1776-1785
Virtual and Reality: An Analysis of the UCLA Virtual Crossmatch Exchanges
The “virtual” crossmatch (VXM) has become a critical tool to predict the compatibility between an organ donor and a potential recipient. Yet, nonstandardized laboratory practice can lead to variability in VXM interpretation. Therefore, UCLA’s VXM Exchange survey was designed to understand factors that influence the variability of VXM prediction in the presence of HLA donor-specific antibody (DSA). Thirty-six donor blood samples and 72 HLA reference sera were sent to 35 participating laboratories to perform HLA antibody testing, flow crossmatch (FXM), and VXM from 2014 to 2019, consisting of 144 T/B-cell FXM pairs and 112 T/B-cell VXM pairs. In the FXM survey, 86% T-cell FXM and 84% B-cell FXM achieved >80% concordance among laboratories. In the VXM survey, 81% T-cell VXM and 80% VXM achieved >80% concordance. The concordance between FXM and VXM was 79% for T cell and 87% for B cell. The consensus between VXM and FXM was high with strong DSA. However, significant variability was observed in sera with (1) very high titer antibodies that exit prozone effect; (2) weak-to-moderate DSA, particularly in the presence of multiple weak DSAs; and (3) DSA against lowly expressed antigens. With the increasing use the VXM, standardization and continuous learning via exchange surveys will provide better understanding and quality controls for VXM to improve accuracy across all centers.
- 20 July 2023
- Published by Wolters Kluwer Health in Transplantation
- Vol. 107 (8) , 1776-1785
Open AccessVirtual and Reality: An Analysis of the UCLA Virtual Crossmatch Exchanges
The “virtual” crossmatch (VXM) has become a critical tool to predict the compatibility between an organ donor and a potential recipient. Yet, nonstandardized laboratory practice can lead to variability in VXM interpretation. Therefore, UCLA’s VXM Exchange survey was designed to understand factors that influence the variability of VXM prediction in the presence of HLA donor-specific antibody (DSA). Thirty-six donor blood samples and 72 HLA reference sera were sent to 35 participating laboratories to perform HLA antibody testing, flow crossmatch (FXM), and VXM from 2014 to 2019, consisting of 144 T/B-cell FXM pairs and 112 T/B-cell VXM pairs. In the FXM survey, 86% T-cell FXM and 84% B-cell FXM achieved >80% concordance among laboratories. In the VXM survey, 81% T-cell VXM and 80% VXM achieved >80% concordance. The concordance between FXM and VXM was 79% for T cell and 87% for B cell. The consensus between VXM and FXM was high with strong DSA. However, significant variability was observed in sera with (1) very high titer antibodies that exit prozone effect; (2) weak-to-moderate DSA, particularly in the presence of multiple weak DSAs; and (3) DSA against lowly expressed antigens. With the increasing use the VXM, standardization and continuous learning via exchange surveys will provide better understanding and quality controls for VXM to improve accuracy across all centers.
- 26 August 2022
- Published by Elsevier in Human Immunology
- Vol. 83 (10) , 674-686
Current donor selection strategies for allogeneic hematopoietic cell transplantation
- 26 August 2022
- Published by Elsevier in Human Immunology
- Vol. 83 (10) , 674-686
Current donor selection strategies for allogeneic hematopoietic cell transplantation
- 11 August 2022
- Published by Elsevier in Human Immunology
- Vol. 83 (10) , 695-703
Donor selection based on NK alloreactivity for patients with hematological malignancies
- 11 August 2022
- Published by Elsevier in Human Immunology
- Vol. 83 (10) , 695-703
Donor selection based on NK alloreactivity for patients with hematological malignancies
- Open Access
- 1 February 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (2) , 565-573
The allograft injury marker CXCL9 determines prognosis of anti-HLA antibodies after lung transplantation
- 1 February 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (2) , 565-573
Open AccessThe allograft injury marker CXCL9 determines prognosis of anti-HLA antibodies after lung transplantation
- 1 November 2021
- Published by Elsevier in Human Immunology
- Vol. 82 (11) , 812-819
Challenges in the application of NGS in the clinical laboratory
- 1 November 2021
- Published by Elsevier in Human Immunology
- Vol. 82 (11) , 812-819
Challenges in the application of NGS in the clinical laboratory
- Open Access
- 30 May 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 8067
Integrate CRISPR/Cas9 for protein expression of HLA-B*38:68Q via precise gene editing
The determination of null- or low-expressed HLA alleles is clinically relevant in both hematopoietic stem cell transplantation and solid organ transplantation. We studied the expression level of a questionable (Q)HLA-B*38:68Qallele, which carries a 9-nucleotide (nt) deletion at codon 230–232 in exon 4 ofHLA-B*38:01:01:01using CRISPR/Cas9 gene editing technology. CRISPR/Cas9 gene editing ofHLA-B*38:01:01:01homozygous EBV B cell line resulted in oneHLA-B*38:68Q/B*38:01:01:01heterozygous and oneHLA-B*38:68Qhomozygous clone. Flow cytometric analysis of monoclonal anti-Bw4 antibody showed the protein expression ofHLA-B*38:01:01:01in homozygous cells was 2.2 fold higher thanHLA-B*38:68Q/B*38:01:01:01heterozygous cells, and the expression ofHLA-B*38:68Q/B*38:01:01:01heterozygous cells was over 2.0 fold higher thanHLA-B*38:68Qhomozygous cells. TheHLA-B*38:68Qexpression was further confirmed using anti-B38 polyclonal antibody. Similarly, the expression of theHLA-B*38:01:01:01homozygous cells was 1.5 fold higher than that ofHLA-B*38:68Q/B*38:01:01:01heterozygous cells, and theHLA-B*38:68Q/B*38:01:01:01heterozygous cells was over 1.6 fold higher than that ofHLA-B*38:68Qhomozygous cells. The treatment ofHLA-B*38:68Qhomozygous cells with IFN-γ significantly increased its expression. In conclusion, we demonstrate thatHLA-B*38:68Qis a low-expressing HLA allele. The CRISPR/Cas9 technology is a useful tool to induce precise gene editing in HLA genes to enable the characterization of HLA gene variants on expression and function.
- 30 May 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 8067
Open AccessIntegrate CRISPR/Cas9 for protein expression of HLA-B*38:68Q via precise gene editing
The determination of null- or low-expressed HLA alleles is clinically relevant in both hematopoietic stem cell transplantation and solid organ transplantation. We studied the expression level of a questionable (Q)HLA-B*38:68Qallele, which carries a 9-nucleotide (nt) deletion at codon 230–232 in exon 4 ofHLA-B*38:01:01:01using CRISPR/Cas9 gene editing technology. CRISPR/Cas9 gene editing ofHLA-B*38:01:01:01homozygous EBV B cell line resulted in oneHLA-B*38:68Q/B*38:01:01:01heterozygous and oneHLA-B*38:68Qhomozygous clone. Flow cytometric analysis of monoclonal anti-Bw4 antibody showed the protein expression ofHLA-B*38:01:01:01in homozygous cells was 2.2 fold higher thanHLA-B*38:68Q/B*38:01:01:01heterozygous cells, and the expression ofHLA-B*38:68Q/B*38:01:01:01heterozygous cells was over 2.0 fold higher thanHLA-B*38:68Qhomozygous cells. TheHLA-B*38:68Qexpression was further confirmed using anti-B38 polyclonal antibody. Similarly, the expression of theHLA-B*38:01:01:01homozygous cells was 1.5 fold higher than that ofHLA-B*38:68Q/B*38:01:01:01heterozygous cells, and theHLA-B*38:68Q/B*38:01:01:01heterozygous cells was over 1.6 fold higher than that ofHLA-B*38:68Qhomozygous cells. The treatment ofHLA-B*38:68Qhomozygous cells with IFN-γ significantly increased its expression. In conclusion, we demonstrate thatHLA-B*38:68Qis a low-expressing HLA allele. The CRISPR/Cas9 technology is a useful tool to induce precise gene editing in HLA genes to enable the characterization of HLA gene variants on expression and function.